Literature DB >> 2172287

Serodiagnosis of infectious mononucleosis by using recombinant Epstein-Barr virus antigens and enzyme-linked immunosorbent assay technology.

M Gorgievski-Hrisoho1, W Hinderer, H Nebel-Schickel, J Horn, R Vornhagen, H H Sonneborn, H Wolf, G Siegl.   

Abstract

Four recombinant, diagnostically useful Epstein-Barr virus (EBV) proteins representative of the viral capsid antigen (p150), diffuse early antigen (p54), the major DNA-binding protein (p138), and the EBV nuclear antigen (p72) (W. Hinderer, H. Nebel-Schickel, H.H. Sonneborn, M. Motz, R. Kühbeck, and H. Wolf, J. Exp. Clin. Cancer Res. 7[Suppl.]:132, 1988) were used to set up individual enzyme-linked immunosorbent assays (ELISAs) for the qualitative and quantitative detection of immunoglobulin M (IgM) and IgG antibodies. In direct comparison with results obtained by standard immunofluorescence or immunoperoxidase assays, it was then shown that the recombinant EBV ELISAs provide the means for specific and sensitive serodiagnosis of infectious mononucleosis (IM) caused by EBV. The most useful markers in sera from such patients proved to be IgM antibodies against p54, p138, and p150. Additional positive markers for recent or ongoing IM apparently were IgG antibodies against p54 and p138. In contrast, anti-p72 IgG had a high preference for sera from healthy blood donors and, therefore, can be considered indicative of past exposure to the virus. Altogether, the individual ELISAs proved to be as specific and at least as sensitive for the diagnosis of IM as the currently available standard techniques are. Moreover, our findings suggest that, by combining individual test antigens, a workable ELISA system consisting of three assays (IgM against p54, p138, and p150; IgG against p54 and p138; and IgG against p72) can be established for the standardized rapid diagnosis of acute EBV infections.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2172287      PMCID: PMC268167          DOI: 10.1128/jcm.28.10.2305-2311.1990

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Rheumatoid factor as a cause of positive reactions in tests for Epstein-Barr virus-specific IgM antibodies.

Authors:  G Henle; E T Lennette; M A Alspaugh; W Henle
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

2.  A prospective evaluation of heterophile and Epstein-Barr virus-specific IgM antibody tests in clinical and subclinical infectious mononucleosis: Specificity and sensitivity of the tests and persistence of antibody.

Authors:  A S Evans; J C Niederman; L C Cenabre; B West; V A Richards
Journal:  J Infect Dis       Date:  1975-11       Impact factor: 5.226

3.  Reaction of antibodies to rheumatoid arthritis nuclear antigen with a synthetic peptide corresponding to part of Epstein-Barr nuclear antigen 1.

Authors:  P J Venables; T Pawlowski; P A Mumford; C Brown; D H Crawford; R N Maini
Journal:  Ann Rheum Dis       Date:  1988-04       Impact factor: 19.103

Review 4.  Epstein-Barr virus specific diagnostic tests in infectious mononucleosis.

Authors:  W Henle; G E Henle; C A Horwitz
Journal:  Hum Pathol       Date:  1974-09       Impact factor: 3.466

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Electroblotting of multiple gels: a simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose.

Authors:  J Kyhse-Andersen
Journal:  J Biochem Biophys Methods       Date:  1984-12

7.  Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity.

Authors:  J S Li; B S Zhou; G E Dutschman; S P Grill; R S Tan; Y C Cheng
Journal:  J Virol       Date:  1987-09       Impact factor: 5.103

8.  Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

Authors:  W Henle; G Henle; J Andersson; I Ernberg; G Klein; C A Horwitz; G Marklund; L Rymo; C Wellinder; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

9.  Epstein-Barr virus infectious mononucleosis in children. II. Heterophil antibody and viral-specific responses.

Authors:  C V Sumaya; Y Ench
Journal:  Pediatrics       Date:  1985-06       Impact factor: 7.124

10.  Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen.

Authors:  G Rhodes; H Rumpold; P Kurki; K M Patrick; D A Carson; J H Vaughan
Journal:  J Exp Med       Date:  1987-04-01       Impact factor: 14.307

View more
  13 in total

1.  Reliability of four methods for the diagnosis of acute infection by Epstein-Barr virus.

Authors:  J Gutiérrez; M Rodríguez; C Maroto; G Piédrola
Journal:  J Clin Lab Anal       Date:  1997       Impact factor: 2.352

2.  Antibodies to lytic infection proteins in lymphocryptovirus-infected rhesus macaques: a model for humoral immune responses to epstein-barr virus infection.

Authors:  Nina Orlova; Mark H Fogg; Angela Carville; Fred Wang
Journal:  Clin Vaccine Immunol       Date:  2011-07-06

3.  Epstein-Barr virus and disease activity in multiple sclerosis.

Authors:  D Buljevac; G J J van Doornum; H Z Flach; J Groen; A D M E Osterhaus; W Hop; P A van Doorn; F G A van der Meché; R Q Hintzen
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-10       Impact factor: 10.154

4.  Evaluation of two slide agglutination tests and a novel immunochromatographic assay for rapid diagnosis of infectious mononucleosis.

Authors:  M C Gómez; J A Nieto; M A Escribano
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

5.  Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation.

Authors:  M Buisson; B Fleurent; M Mak; P Morand; L Chan; A Ng; M Guan; D Chin; J M Seigneurin
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

6.  Cross-reactivity of Epstein-Barr virus-specific immunoglobulin M antibodies with cytomegalovirus antigens containing glycine homopolymers.

Authors:  D Lang; R Vornhagen; M Rothe; W Hinderer; H H Sonneborn; B Plachter
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

7.  Clinical reliability of IgG, IgA, and IgM antibodies in detecting Epstein-Barr virus at different stages of infection with a commercial nonrecombinant polyantigenic ELISA.

Authors:  J Gutiérrez; M J Vergara; G Piédrola; M C Maroto
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

8.  Evaluation of three commercial enzyme-linked immunosorbent assays and two latex agglutination assays for diagnosis of primary Epstein-Barr virus infection.

Authors:  A Svahn; M Magnusson; L Jägdahl; L Schloss; G Kahlmeter; A Linde
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

9.  Early serodiagnosis of acute human cytomegalovirus infection by enzyme-linked immunosorbent assay using recombinant antigens.

Authors:  R Vornhagen; B Plachter; W Hinderer; T H The; J Van Zanten; L Matter; C A Schmidt; H H Sonneborn; G Jahn
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

10.  Development of a recombinant enzyme-linked immunosorbent assay for detection of antibodies against Epstein-Barr virus nuclear antigens 2A and 2B.

Authors:  R Geertsen; A Espander-Jansson; M Dobec; P Price; W Wunderli; L Rymo
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.